Terminated PHASE1 INTERVENTIONAL 1-arm NCT00816478

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Sponsor: Northwell Health

Conditions Focal Segmental Glomerulosclerosis

Interventions Galactose

Updated 6 times since 2017 Last updated: Sep 8, 2015 Started: Dec 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study closed by Institutional Review Board

Other terminated trials from Northwell Health

See all terminations from Northwell Health

Other Focal Segmental Glomerulosclerosis trials with similar outcome

Browse all Focal Segmental Glomerulosclerosis trials

A PHASE1 clinical study on Focal Segmental Glomerulosclerosis, this trial is terminated or withdrawn. The trial is conducted by Northwell Health and has accumulated 6 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Northwell Health

Data source: Northwell Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.